We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > NUZYRA

News List

Paratek Pharmaceuticals Announces FDA Orphan Drug Designation for NUZYRA (omadacycline) for the Treatment of Infections Caused by Nontuberculous Mycobacteria firstwordpharma
August 19, 2021
Paratek Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted the company orphan drug designation for NUZYRA® (omadacycline) for the treatment of infections
Paratek Announces FDA Approval of NUZYRA® for Treatment of Community-Acquired Bacterial Pneumonia americanpharmaceuticalreview
June 04, 2021
Paratek Pharmaceuticals Inc. announced that the U.S. FDA has approved the Company’s supplemental New Drug Application (sNDA) for the oral-only dosing regimen of NUZYRA® for the treatment of adults with Community-Acquired Bacterial Pneumonia (CABP).
Paratek Gets BARDA Funding for NUZYRA Supply contractpharma
April 03, 2020
To support the development and manufacturing activities of NUZYRA for the treatment of pulmonary anthrax.
Paratek Submits pre-Emergency Use Authorization Application for NUZYRA americanpharmaceuticalreview
March 12, 2020
Paratek Pharmaceuticals announced that a pre-emergency use authorization (EUA) application for NUZYRA (omadacycline) has been submitted to the U.S. Food and Drug Administration (FDA).